Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular ...

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22% ...

Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months

Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...
Yahoo

Ocugen doses first subject in trial of modifier gene therapy candidate

Add Yahoo as a preferred source to see more of our stories on Google. A genetic eye disorder Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, ...
sharewise

OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch

Ocugen OCGN is pushing three retinal gene therapy programs toward late-stage milestones, with multiple data readouts and ...
EurekAlert!

ALG6 acts as a modifier gene in the inherited genetic eye disease retinitis pigmentosa 59

BIRMINGHAM, Ala. – Modifier genes add complexity to precision medicine. A modifier gene is one that has genetic variants such as single nucleotide changes that differ from the most common sequence in ...
Healio

Early positive data reported for geographic atrophy modifier gene therapy

Please provide your email address to receive an email when new articles are posted on . Low-dose OCU410 slowed lesion growth, preserved retinal tissue and stabilized visual function in three patients.
Nasdaq

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the ...
Seeking Alpha

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN) (Ocugen or the Company), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United ...
Nasdaq

Ocugen, Inc. to Showcase Innovative Modifier Gene Therapy Platform at Upcoming ARVO and Retina World Congress Meetings

Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced its participation in two significant upcoming conferences: the ARVO 2025 Annual Meeting in Salt Lake ...
Seeking Alpha

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN) (Ocugen or the Company), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the ...
Kaleido Scope

ALG6 acts as a modifier gene in the inherited genetic eye disease retinitis pigmentosa 59

Steven Pittler, Ph.D., at the University of Alabama at Birmingham has sought to find modifier genes for the hereditary eye disorder retinitis pigmentosa type 59. After onset in one’s late teens, RP59 ...